

RESOURCES/REFERENCES

1. World Health Organization. *Gender and Aging*. [WHO Website.] Available at: <http://www.who.int/entity/en/>. Accessed August 15, 2012.
2. U.S. Department of Health & Human Services. National Institutes of Health. Office of Research on Women's Health. [U.S. Department of Health & Human Services Website.] Available at: <http://www4.od.nih.gov/orwh>. Accessed October 5, 2012.
3. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002; 288(3): 321–333.
4. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. *JAMA* 2004; 291(14): 1701–1712.
5. Hulley S, Grady D, Bush T et al; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998; 280(7): 605–613.
6. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. *JAMA* 2003; 289(20): 2651–2662.
7. Stampfer MJ, Colditz GA, Willet WC et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. *N Engl J Med* 1991; 325(11): 756–762.
8. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. *Annu Rev Public Health* 2005; 26: 115–140.
9. Lisabeth LD, Beiser AS, Brown DL et al. Age at natural menopause and risk of ischemic stroke: The Framingham Heart Study. *Stroke* 2009; 40(4): 1044–1049.
10. Quyyumi AA. Women and ischemic heart disease: Pathophysiologic implications from the Women's Ischemia Syndrome Evaluation (WISE) study and future research steps. *J Am Coll Cardiol* 2006; 47(3 Suppl): S66–S71.
11. Holt-Waldo N, Stephenson K. The lived experience of perimenopausal and menopausal women undergoing treatment with bioidentical human hormones. *IJPC* 2007; 11(4): 292–296.
12. Folsom AR. Hemostatic risk factors for atherothrombotic disease: An epidemiologic view. *Thromb Haemost* 2001; 86(1): 366–373.
13. Levi M, van der poll T, Büller HR. Bidirectional relation between inflammation and coagulation. *Circulation* 2004; 109(22): 2698–2704.
14. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. *Am J Cardiol* 2002; 90(1A): 7F–10F.
15. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. *Cardiovasc Res* 2002; 53(3): 597–604.
16. Rossouw JE, Cushman M, Greenland P et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative Trials of hormone therapy. *Arch Intern Med* 2008; 166(20): 2245–2253.
17. Eskandari F, Mistry S, Martinez PE et al. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: Implications for greater cardiovascular risk. *Metabolism* 2005; 54(7): 918–924.
18. Jespersen J, Munkvad S, Gram JB. The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima. *Dan Med Bull* 1993; 40(4): 495–502.
19. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. *Lipids* 2005; 40(12): 1215–1220.
20. Zakai NA, Katz R, Jenny NS et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: The Cardiovascular Health Study. *J Thromb Haemost* 2007; 5(6): 1128–1135.
21. Thurston RC, Sutton-Tyrell K, Everson-Rose SA et al. Hot flashes and subclinical cardiovascular disease: Findings from the Study of Women's Health Across the Nation Heart Study. *Circulation* 2008; 118(12): 1234–1240.

22. Tzoulaki I, Murray GD, Price JF et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: The Edinburgh Artery Study. *Am J Epidemiol* 2006; 163(4): 334–341.
23. Danesh J, Collins R, Appleby P et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. *JAMA* 1998; 279(18): 1477–1482.
24. Thurston RC, Khoukhar SR, Sutton-Tyrrell K, et al. Are vasomotor symptoms associated with alternations in hemostatic and inflammatory markers? Finding from the Study of Women's Health Across the Nation. *Meno-pause* 2011; 18(10):1044-1051.
25. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. *Thromb Haemost* 1994; 71(4): 420–423.
26. Wright D, Poller L, Thomson JM et al. The effect of hormone replacement therapy of the age-related rise of factor VIIc, and its activity state. *Thromb Res* 1997; 85(6): 455–464.
27. Braunstein JB, Kershner DW, Bray P et al. Interaction of hemostatic genetics with hormone therapy: New insights to explain arterial thrombosis in postmenopausal women. *Chest* 2002; 121(3): 906–920.
28. Hermsmeyer RK, Thompson TL, Pohost GM et al. Cardiovascular effects of medroxyprogesterone acetate and progesterone: A case of mistaken identity? *Nat Clin Pract Cardiovasc Med* 2008; 5(7): 387–395.
29. Barrett-Connor E. Hormones and heart disease in women: Where are we in 2005? *Curr Atheroscler Rep* 2006; 8(2): 85–87.
30. Bladbjerg EM, Skouby SO, Andersen LF et al. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. *Hum Reprod* 2002; 17(12): 3235–3241.
31. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. *J Pharmacol Exp Ther* 2004; 308(2): 403–409.
32. Psaty BM, Smith NL, Lemaitre RN et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. *JAMA* 2001; 285(7): 906–913.
33. Chlebowski RT, Kuller LH, Prentice RL et al; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. *N Engl J Med* 2009; 360(6): 573–587.
34. Sowers MR, Matthews KA, Jannausch M et al. Hemostatic factors and estrogen during the menopausal transition. *J Clin Endocrinol Metab* 2005; 90(11): 5942–5948.
35. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet* 2003; 362(9382): 428–432.
36. Kip KE, Marroquin OC, Shaw LF et al. Global inflammation predicts cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. *Am Heart J* 2005; 150(5): 900–906.
37. Sherman S, Miller H, Nerurkar L et al. Research opportunities for reducing the burden of menopause-related symptoms. *Am J Med* 2005; 118(Suppl 12B): 166–171.
38. Crandall C, Palla S, Reboussin B et al. Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial. *J Womens Health (Larchmt)* 2006; 15(1): 14–23.
39. Kaplan RC, McGinn AP, Baird AE et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: The Women's Health Initiative Observational Study. *J Stroke Cerebrovasc Dis* 2008; 17(6): 344–355.
40. Ridker PM, Hennekens CH, Rifai N et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. *Circulation* 1999; 100(7): 713–716.
41. Rossouw JE, Cushman M, Greenland P et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative Trials of hormone therapy. *Arch Intern Med* 2008; 166(20): 2245–2253.
42. van Baal WM, Kenemans P, van der Mooren MJ et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. *Thromb Haemost* 1999; 81(6): 925–928.
43. Reuben DB, Palla SL, Hu P et al. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. *Am J Med* 2006; 119(2): 167.

44. Kurtz EG, Ridker PM, Rose LM et al. Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes. *Menopause* 2011; 18(1): 23–29.
45. Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation* 1998; 98(8): 731–733.
46. Komulainen P, Lakka TA, Kivipelto M et al. Serum high sensitivity C-reactive protein and cognitive function in elderly women. *Age Ageing* 2007; 36(4): 443–448.
47. Elenkov IJ, Chrousos GP. Stress, cytokine patterns and susceptibility to disease. *Baillieres Best Pract Res Clin Endocrinol Metab* 1999; 13(4): 583–595.
48. Kim OY, Chae JS, Paik JK et al. Effects of aging and menopause on serum interleukin-6 levels and peripheral blood mononuclear cell cytokine production in healthy nonobese women. *Age (Dordr)* 2012; 34(2): 415–425.
49. Hawkey LC, Cacioppo JT. Stress and the aging immune system. *Brain Behav Immun* 2004; 18(2): 114–119.
50. Kamada M, Irahara M, Maegawa M et al. Transient increase in the levels of T-helper 1 cytokines in postmenopausal women and the effects of hormone replacement therapy. *Gynecol Obstet Invest* 2001; 52(2): 82–88.
51. Kamada M, Irahara M, Maegawa M, Yasui T, Yamano S, Yamada M, Tezuka M, Kasai Y, Deguchi K, Ohmoto Y, Aono T. B cell subsets in postmenopausal women and the effect of hormone replacement therapy. *Maturitas*. 2001 Jan 31;37(3):173-9.
52. Brooks-Asplund EM, Tupper CE, Daun JM et al. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. *Cytokine* 2002; 19(4): 193–200.
53. Khan KN, Masuzaki H, Fujishita A et al. Interleukin-6 and tumor necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cell and its involvement in the growth of endometriosis. *Hum Reprod* 2005; 20(10): 2715–2723.
54. Papanicolaou DA, Wilder RL, Manolagas SC et al. The pathophysiologic roles of interleukin-6 in human disease. *Ann Intern Med* 1998; 128(2): 127–137.
55. Pawelec G, Hirokawa K, Fülöp T. Altered T cell signalling in ageing. *Mech Ageing Dev* 2001; 122(14): 1613–1637.
56. Glaser R, MacCallum RC, Laskowski BF et al. Evidence for a shift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. *J Gerontol A Biol Sci Med Sci* 2001; 56(8): M477–M482.
57. Gunter MJ, Hoover DR, Yu H et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 2009; 101(1): 48–60.
58. Cappola AR, Xue QL, Ferrucci L et al. Insulin-like Growth Factor I and Interleukin-6 contribute synergistically to disability and mortality in older women. *J Clin Endocrinol Metab* 2003; 88(5): 2019–2025.
59. Hu P, Greendale GA, Palla SL et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The postmenopausal estrogen progestin intervention (PEPI) trial. *Atherosclerosis* 2006; 185(2): 347–352.
60. Black PH. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. *Brain Behav Immun* 2003; 17(5): 350–364.
61. Elenkov IJ. Systemic stress-induced Th2 shift and its clinical implications. *Int Rev Neurobiol* 2002; 52: 163–186.
62. Heim C, Newport DJ, Wagner D et al. The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: A multiple regression analysis. *Depress Anxiety* 2002; 15(3): 117–125.
63. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. *J Psychosom Res* 2002; 52(1): 1–23.
64. Lavoie KL, Miller SB, Conway M et al. Anger, negative emotions, and cardiovascular reactivity during interpersonal conflict in women. *J Psychosom Res* 2001; 51(3): 503–512.
65. Shaw LJ, Bairey Merz CN, Pepine CJ et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) study: Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. *J Am Coll Cardiol* 2006; 47(3 Suppl): S4–S20.
66. Gierach GL, Johnson BD, Bairey Merz CN et al. Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation

- (WISE) Study. *J Am Coll Cardiol* 2006; 47(3 Suppl): S50–S58.
67. Olson MB, Krantz DS, Kelsey SF et al. Hostility scores are associated with increased risk of cardiovascular events in women undergoing coronary angiography: A report from the NHLBI-Sponsored WISE Study. *Psychosom Med* 2005; 67(4): 546–552.
 68. Bromberger JT, Matthews KA, Schott LL et al. Depressive symptoms during the menopausal transition: The Study of Women's Health Across the Nation (SWAN). *J Affect Disord* 2007; 103(1–3): 267–272.
 69. Soares CN. Can depression be a menopause-associated risk? *BMC Med* 2010; 8: 79–84.
 70. Baca-Garcia E, Diaz-Sastre C, Ceverino A et al. Suicide attempts among women during low estradiol/progesterone states. *J Psychiatri Res* 2009; 44(4): 209–214.
 71. Eskandari F, Mistry S, Martinez PE et al; POWER (Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Study Group. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: Implications for greater cardiovascular risk. *Metabolism* 2005; 54(7): 918–924.
 72. Pitsavos C, Panagiotakos DB, Papageorgiou C et al. Anxiety in relation to inflammation and coagulation markers, among healthy adults: The ATTICA Study. *Atherosclerosis* 2006; 185(2): 320–326.
 73. Hochschild A. *The Second Shift*. New York, NY: Penguin Books; 1989.
 74. Stephenson K. *Awakening Athena: Resilience, Restoration, and Rejuvenation for Women*. Tyler, TX: Health, Heart & Mind Institute; 2004.
 75. Frankenhaeuser M. Challenge-control interaction as reflected in sympathetic-adrenal and pituitary-adrenal activity: Comparison between the sexes. *Scand J Psychol* 1982; Suppl 1: 158–164.
 76. Frankenhaeuser M. A biopsychosocial approach to stress in women and men. In: Adesso VJ, Reddy DM, Fleming R, eds. *Psychological Perspectives on Women's Health*. New York, NY: Taylor and Francis; 1992: 39–56.
 77. Beer J, Beer J. Burnout and stress, depression and self-esteem of teachers. *Psychol Rep* 1992; 71(3 Pt 2):1331–1336.
 78. Luecken LJ, Suarez EC, Kuhm CM et al. Stress in employed women: Impact of marital status and children at home on neurohormone output and home strain. *Psychosom Med* 1997; 59(4): 352–359.
 79. Elenkov IJ, Webster EL, Torpy DJ et al. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: Acute and chronic effects. *Ann N Y Acad Sci* 1999; 876: 1–11.
 80. Elenkov IJ. Systemic stress-induced Th2 shift and its clinical implications. *Int Rev Neurobiol* 2002; 52: 163–186.
 81. Lovallo WR, Gerin W. Psychophysiological reactivity: Mechanisms and pathways to cardiovascular disease. *Psychosom Med* 2003; 65(1): 36–45.
 82. Vrijkotte TG, van Doornen LJ, de Geus EJ. Work stress and metabolic and hemostatic risk factors. *Psychosom Med* 1999; 61(6): 796–805.
 83. Vrijkotte TG, van Doornen LJ, de Geus EJ. Overcommitment to work is associated with changes in cardiac sympathetic regulation. *Psychosom Med* 2004; 66(5): 656–663.
 84. Kunz-Ebrecht SR, Mohamed-Ali V, Feldman PJ et al. Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines. *Brain Behav Immun* 2003; 17(5): 373–383.
 85. Padgett DA, Glaser R. How stress influences the immune response. *Trends Immunol* 2003; 24(8): 444–448.
 86. Segerstrom SC, Miller GE. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry. *Psych Bull* 2004; 130(4): 601–630.
 87. Uchino BN, Cacioppo JT, Kiecolt-Glaser JK. The relationship between social support and physiological processes: A review with emphasis on underlying mechanisms and implications for health. *Psychol Bull* 1996; 119(3): 488–531.
 88. Harman D. Aging: A theory based on free radical and radiation chemistry. *J Gerontol* 2007; 11(3): 298–300.
 89. De Magalhaes JP. An educational resource on the science of aging. *Senescence* 2007.
 90. Hertoghe T. The “multiple hormone deficiency” theory of aging: Is human senescence caused mainly by multiple hormone deficiencies? *Ann N Y Acad Sci* 2005; 1057: 448–465.

91. Kelley KW. From hormones to immunity: The physiology of immunology. *Brain Behav Immun* 2004; 18(2): 95–113.
92. Sabia S, Fournier A, Mesrine S et al. Risk of onset of menopausal symptoms in periods surrounding menopause. *Maturitas* 2007; 58(4): 340–347.
93. Ferrari E, Mirani M, Barili L et al. Cognitive and affective disorders in the elderly: A neuroendocrine study. *Arch Gerontol Geriatr Suppl* 2004; 9: 171–182.
94. Bonomo SM, Rigamonti AE, Giunta M et al. Menopausal transition: A possible risk factor for brain pathologic events. *Neurobiol Aging* 2009; 30(1): 71–80.
95. Buckley TM, Schatzberg AF. Aging and the role of the HPA axis and rhythm in sleep and memory-consolidation. *Am J Geriatr Psychiatry* 2005; 13(5): 344–352.
96. Ferrari E, Mirani M, Barili L et al. Cognitive and affective disorders in the elderly: A neuroendocrine study. *Arch Gerontol Geriatr Suppl* 2004; 9: 171–182.
97. Antonijevic IA, Murck H, Frieboes RM et al. On the role of menopause for sleep-endocrine alterations associated with major depression. *Psychoneuroendocrinology* 2003; 28(3): 401–418.
98. Roux JP, Stephenson K, Kapur S et al. Neuroendocrine, inflammatory, and immune biomarkers associated with body composition, depression, and cognitive impairment in elderly men and women. Presented at the Cleveland Clinic Heart and Brain Summit 2010. Las Vegas, Nevada. *CCJM* 2011; 8(78[Suppl 1]): S101.
99. Murialdo G, Barreca A, Nobili F et al. Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-1 system in dementia. *J Endocrinol Invest* 2001; 24(3): 139–146.
100. Sin DD, Cohen SB, Day A et al. Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women. *Proc Am Thorac Soc* 2007; 4(8): 671–674.
101. Real FG, Svanes C, Omenaas ER et al. Lung function, respiratory symptoms, and the menopausal transition. *J Allergy Clin Immunol* 2008; 121(1): 72–80.
102. Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. *Thorax* 1999; 54(12): 1119–1138.
103. Straczek C, Oger E, Yon de Jonage-Canonica MB et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. *Circulation* 2005; 112(22): 3495–3500.
104. Canonico M, Oger E, Plu-Bureau G et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER Study. *Circulation* 2007; 115(7): 840–845.
105. Stephenson K, Neuenschwander PF, Kurdowska AK et al. Transdermal progesterone: Effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women. *IJPC* 2008; 12(4): 295–304.
106. Spearoff L, Glass Kase N. *Clinical Gynecologic Endocrinology and Infertility*. Baltimore, MD: Williams and Wilkins;
107. Waddell BJ, O'Leary PC. Distribution and metabolism of topically applied progesterone in a rat model. *J Steroid Biochem Mol Biol* 2002; 80(4–5): 449–455.
108. Stephenson K, Price C, Kurdowska A et al. Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, California. December 2004. *Blood* 2004; 104(11 Pt 1): 414b–415b.
109. Prior JC. Ovarian aging and the perimenopausal transition: The paradox of endogenous ovarian hyperstimulation. *Endocrine* 2005; 26(3): 297–300.
110. Montplaisir J, Lorrain J, Denesle R et al. Sleep in menopause: Differential effects of two forms of hormone replacement therapy. *Menopause* 2001; 8(1): 10–16.
111. Plu-Bureau G, Lê MG, Thalabard JC et al. Percutaneous progesterone use and risk of breast cancer: Results from a French cohort study of premenopausal women with benign breast disease. *Cancer Detect Prev* 1999; 23(4): 290–296.
112. Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: A cross-sectional survey. *J Womens Health Gend Based Med* 2000; 9(4): 381–387.

113. Anasti JN, Leonetti HB, Wilson KJ. Topical progesterone cream has antiproliferative effect on estrogen-stimulated endometrium. *Obstet Gynecol* 2001;97:S10
114. Leonetti HB, Longo S, Anasti JN. Topical progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol* 1999; 94(2): 225–228.
115. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse effects on Bcl-2 and p53. *Ann Clin Lab Sci* 1998; 28(6): 360–369.
116. Hermsmeyer RK, Mishra RG, Pavcnik D et al. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. *ArteriosclerThromb Vasc Biol* 2004; 24(5): 955–961.
117. Carmody BJ, Arora S, Wakefield MC et al. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. *J Vasc Surg* 2002; 36(4): 833–888.
118. Hermsmeyer K, Miyagawa K, Kelley ST et al. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys. *J Am Coll Cardiol* 1997; 29(3): 671–680.
119. Minshall RD, Stanczyk FZ, Miyagawa K et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. *J Clin Endocrinol Metab* 1998; 83(2): 649–659.
120. Minshall RD, Pavcnik D, Halushka PV et al. Progesterone regulation of vascular thromboxane A(2) receptors in rhesus monkeys. *Am J Physiol Heart Circ Physiol* 2001; 281(4): H1498–H1507.
121. Rosano GM, Webb CM, Chierchia S et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. *J Am Coll Cardiol* 2000; 36(7): 2154–2159.
122. Schmidt M, Renner C, Löffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. *J Endocrinol* 1998; 158(3): 401–407.
123. Azcoitia I, Leonelli E, Magnaghi V et al. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. *Neurobiol Aging* 2003; 24(6): 853–860.
124. Bumke-Vogt C, Bähr V, Diederich S et al. Expression of the progesterone receptor and progesterone-metabolizing enzymes in the female and male human kidney. *J Endocrinol* 2002; 175(2): 349–364.
125. Mircioiu C, Perju A, Griu E et al. Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. *Eur J Drug Metab Pharmacokinet* 1998; 23(3): 397–402.
126. DeMasi MA. Hormonally associated migraine. *The Female Patient* 2004; 29(7): 30–36.
127. Jette N, Morrell MJ. Sex-steroid hormones in women with epilepsy. *Am J Electroneurodiagnostic Technol* 2005; 45(1): 36–48.
128. Dai D, Wolf DM, Litman ES et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: Down-regulation of cellular adhesion molecules through progesterone B receptors. *Cancer Res* 2002; 62(3): 881–886.
129. Gruber DM, Sator MO, Wieser F et al. Progesterone and neurology. *Gynecol Endocrinol* 1999; 13(Suppl 4):41–45.
130. Sternberg WF, Chesler EJ, Wilson SG et al. Acute progesterone can recruit sex-specific neurochemical mechanisms mediating swim stress-induced and kappa-opioid analgesia in mice. *Horm Behav* 2004; 46(4): 467–473.
131. Unger J, Cady R, Farmer-Cady K. Migraine headaches, part 3: Hormonal factors. *The Female Patient* 2003; 28(7): 31–34.
132. Minshall RD, Pavcnik D, Halushka PV et al. Progesterone regulation of vascular thromboxane A(2) receptors in rhesus monkeys. *Am J Physiol Heart Circ Physiol* 2001; 281(4): H1498–H1507.
133. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: Effects mediated via sigma receptors. *J Neurosci* 1996; 16(3): 1193–1202.
134. Ren K, Wei F, Dubner R et al. Progesterone attenuates persistent inflammatory hyperalgesia in female rats: Involvement of spinal NMDA receptor mechanisms. *Brain Res* 2000; 865(2): 272–277.
135. Rosano GM, Webb CM, Chierchia S et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exer-

- cise-induced myocardial ischemia in postmenopausal women. *J Am Coll Cardiol* 2000; 36(7): 2154–2159.
136. Langrish JP, Mills NL, Bath LE et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension* 2009; 53(5): 805–811.
 137. Hermsmeyer RK, Mishra RG, Pavcnik D et al. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. *Arterioscler Thromb Vasc Biol* 2004; 24(5): 955–961.
 138. Azcoitia I, Leonelli E, Magnaghi V et al. Progesterone and its derivatives dihydropregesterone and tetrahydropregesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. *Neurobiol Aging* 2003; 24(6): 853–860.
 139. Minshall R, Pavcnik D, Browne DL et al. Nongenomic vasodilator action of progesterone on primate coronary arteries. *J Appl Physiol* (1985) 2002; 92(2): 701–708.
 140. Choi BC, Polgar K, Xiao L et al. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. *Human Reprod* 2000; 15(Suppl 1): 46–59.
 141. Minshall RD, Miyagawa K, Chadwick CC et al. *In vitro* modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. *FASEB J* 1998; 12(13): 1419–1429.
 142. Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: Blood levels and endometrial protection. *Menopause* 2005; 12(2): 232–237.
 143. Ferrell RJ, O'Connor KA, Rodriguez G et al. Monitoring reproductive aging in a 5-year prospective study: Aggregate and individual changes in steroid hormones and menstrual cycle lengths with age. *Menopause* 2005; 12(5): 567–577.
 144. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. *Am J Obstet Gynecol* 1999; 180(6 Pt 1): 1504–1511.
 145. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: Effects mediated via sigma receptors. *J Neurosci* 1996; 16(3): 1193–1202.
 146. Gruber DM, Sator MO, Wieser F et al. Progesterone and neurology. *Gynecol Endocrinol* 1999; 13(Suppl 4): 41–45.
 147. Rodriguez I, Kilborn MJ, Liu XK et al. Drug-induced QT prolongation in women during the menstrual cycle. *JAMA* 2001; 285(10): 1322–1326.
 148. Minshall RD, Pavcnik D, Halushka PV et al. Progesterone regulation of vascular thromboxane A(2) receptors in rhesus monkeys. *Am J Physiol Heart Circ Physiol* 2001; 281(4): H1498–H1507.
 149. Molloy EJ, O'Neill AJ, Grantham JJ et al. Sex-specific alterations in neutrophil apoptosis: The role of estradiol and progesterone. *Blood* 2003; 102(7): 2653–2663.
 150. Sternberg WF, Chesler EJ, Wilson SG et al. Acute progesterone can recruit sex-specific neurochemical mechanisms mediating swim stress-induced and kappa-opioid analgesia in mice. *Horm Behav* 2004; 46(4): 467–473.
 151. Choi BC, Polgar K, Xiao L et al. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. *Hum Reprod* 2000; 15(Suppl 1): 46–59.
 152. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. *Am J Obstet Gynecol* 1999; 180(6 Pt 1): 1504–1511.
 153. Martin VT, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis—part 1. *Headache* 2006; 46(1): 3–23.
 154. Xilouri M, Papazafiri P. Anti-apoptotic effects of allopregnanolone on P19 neurons. *Eur J Neurosci* 2006; 23(1): 43–54.
 155. Dalton K. *The Premenstrual Syndrome and Progesterone Therapy*. 2nd ed. London, England; Chicago, IL: Year Book Medical Publishers; 1984.
 156. Santoro N, Crawford SL, Lasley WL et al. Factors related to declining luteal function in women during the menopausal transition. *J Clin Endocrinol Metab* 2008; 93(5): 1711–1721.
 157. Beynon HL, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma: Effect of intramuscular progesterone. *Lancet* 1988; 2(8607): 370–372.
 158. Bäckström T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. *Acta Neurol Scand* 1976; 54(4): 321–347.

159. Herzog AG. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. *Neurology* 1986; 36(12): 1607–1610.
160. Miles RA, Paulson RJ, Lobo RA et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: A comparative study. *Fertil Steril* 1994; 62(3): 485–490.
161. Freeman EW, Purdy RH, Coutifaris C et al. Anxiolytic metabolites of progesterone: Correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. *Neuroendocrinology* 1993; 58(4): 478–484.
162. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: Clinical implications for premenstrual syndrome and perimenopause management. *Compr Ther* 1998; 24(6–7): 336–349.
163. Wright DW, Kellermann AL, Hertzberg VS et al. PROTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. *Ann Emerg Med* 2007; 49(4): 391–402.
164. Fournier A, Berrino F, Riboli E et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer* 2005; 114(3): 448–454.
165. Missmer SA, Eliassen AH, Barbieri RL et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. *J Natl Cancer Inst* 2004; 96(24): 1856–1865.
166. Richer JK, Lange CA, Manning NG et al. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. *J Biol Chem* 1998; 273(47): 31317–31326.
167. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. *Breast Cancer Res Treat* 2008; 107(1): 103–111.
168. Pettus EH, Wright DW, Stein DG et al. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res* 2005; 1049(1): 112–119.
169. Sayeed I, Guo Q, Hoffman SW et al. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. *Ann Emerg Med* 2006; 47(4): 381–389.
170. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. *Maturitas* 2003; 46(Suppl 1): S55–S58.
171. Alkhalaf M, El-Mowafy A, Karam S. Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein. *Eur J Cancer Prev* 2002; 11(5): 481–488.
172. Stein DG, Wright DW, Kellerman AL. Does progesterone have neuroprotective properties? *Ann Emerg Med* 2008; 51(2): 164–172.
173. Hermsmeyer RK, Thompson TL, Pohost GM et al. Cardiovascular effects of medroxyprogesterone acetate and progesterone: A case of mistaken identity? *Nat Clin Pract Cardiovasc Med* 2008; 5(7): 387–395.
174. Stein DG. The case for progesterone. *Ann N Y Acad Sci* 2005; 1052: 152–169.
175. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. *JAMA* 2004; 292(18): 2243–2248.
176. de Bruin VM, Vieira MC, Rocha MN et al. Cortisol and dehydroepiandrosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia. *Brain Cogn* 2002; 50(2): 316–323.
177. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Potential remedial effects. *Ann N Y Acad Sci* 1995; 774: 128–142.
178. Morales AJ, Nolan JJ, Nelson JC et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Clin Endocrinol Metab* 1994; 78(6): 1360–1367. Erratum in: *J Clin Endocrinol Metab* 1995; 80(9): 2799.
179. Legrain S, Massien C, Lahlou N et al. Dehydroepiandrosterone replacement administration: Pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. *J Clin Endocrinol Metab* 2000; 85(9): 3208–3217.
180. Labrie F, Diamond P, Cusan L et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 1997; 82(10): 3498–3505.

181. Casson PR, Andersen RN, Herrod HG et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. *Am J Obstet Gynecol* 1993; 169(6): 1536–1539.
182. Casson PR, Faquin LC, Stentz FB et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. *Fertil Steril* 1995; 63(5): 1027–1031.
183. Stomati M, Monteleone P, Casaros E et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. *Gynecol Endocrinol* 2000; 14(5): 342–363.
184. Arlt W, Callies F, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. *N Engl J Med* 1999; 341(14): 1013–1020.
185. Schmidt PJ, Daly RC, Bloch M et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression *Arch Gen Psychiatry* 2005; 62(2): 154–162.
186. Chang DM, Lan JL, Lin HY et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2002; 46(11): 2924–2927.
187. Chang DM, Chu SJ, Chen HC et al. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. *Ann Rheum Dis* 2004; 63(12): 1623–1626.
188. Bachmann G, Bancroft J, Braunstein G et al. Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. *Fertil Steril* 2002; 77(4): 660–665.
189. Notelovitz M. Hot flashes and androgens: A biological rationale for clinical practice. *Mayo Clin Proc* 2004; 79(4 Suppl): S8–S13.
190. Burger HG, Dudley EC, Cui J et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. *J Clin Endocrinol Metab* 2000; 85(8): 2832–2838.
191. Ehrenreich H, Halaris A, Ruether E et al. Psychoendocrine sequelae of chronic testosterone deficiency. *J Psychiatr Res* 1999; 33(5): 379–387.
192. Apperloo MJ, Van Der Stege JG, Hoek A et al. In the mood for sex: The value of androgens. *J Sex Marital Ther* 2003; 29(2): 87–102.
193. Beauchet O. Testosterone and cognitive function: Current clinical evidence of a relationship. *Eur J Endocrinol* 2006; 155(6): 773–781.
194. Jensen MD. Androgen effect on body composition and fat metabolism. *Mayo Clin Proc* 2000; 75(Suppl): S65–S68.
195. Sowers MF, Beebe JL, McConnell D et al. Testosterone concentrations in women aged 25–50 years: Associations with lifestyle, body composition, and ovarian status. *Am J Epidemiol* 2001; 153(3): 256–264.
196. Notelovitz M. Hot flashes and androgens: A biological rationale for clinical practice. *Mayo Clin Proc* 2004; 79(4 Suppl): S8–S13.
197. Burger HG, Dudley EC, Cui J et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. *J Clin Endocrinol Metab* 2000; 85(8): 2832–2838.
198. Ehrenreich H, Halaris A, Ruether E et al. Psychoendocrine sequelae of chronic testosterone deficiency. *J Psychiatr Res* 1999; 33(5): 379–387.
199. Beauchet O. Testosterone and cognitive function: Current clinical evidence of a relationship. *Eur J Endocrinol* 2006; 155(6): 773–781.
200. Jensen MD. Androgen effect on body composition and fat metabolism. *Mayo Clin Proc* 2000; 75(Suppl): S65–S68.
201. Almeida OP. Sex playing with the mind. Effects of oestrogen and testosterone on mood and cognition. *Arg Neuropsychiatr* 1999; 57(3A): 701–706.
202. Fink G, Sumner BE, McQueen JK et al. Sex steroid control of mood, mental state and memory. *Clin Exp Pharmacol Physiol* 1998; 25(10): 764–775.
203. Weber B, Lewicka S, Deuschle M et al. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. *Psychoneuroendocrinology* 2000; 25(8): 765–771.
204. Davis SR, Tran J. Testosterone influences libido and well being in women. *Trends Endocrinol Metab* 2001; 2(1): 33–37.

205. Rohr UD. The impact of testosterone imbalance on depression and women's health. *Maturitas* 2002; 41(Suppl): S25–S46.
206. Notelovitz M. Hot flashes and androgens: A biological rationale for clinical practice. *Mayo Clin Proc* 2004; 79(4 Suppl): S8–S13.
207. Moller J, Einfeldt H. *Testosterone Treatment of Cardiovascular Diseases*. Berlin: Springer Verlag; 1984.
208. Sowers MF, Beebe JL, McConnell D et al. Testosterone concentrations in women aged 25–50 years: Associations with lifestyle, body composition, and ovarian status. *Am J Epidemiol* 2001; 153(3): 256–264.
209. Maurer M, Trajanoski Z, Frey G et al. Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells. *Horm Metab Res* 2001; 33(12): 691–695.
210. Hofling M, Hirschberg A, Skoog L et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. *Menopause* 2007; 14(2): 183–190.
211. Monjo M, Rodriguez AM, Palou A et al. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: Potential mechanism for gender-dependent thermogenesis. *Endocrinology* 2003; 144(11): 4923–4930.
212. Weber B, Lewicka S, Deuschle M et al. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. *Psychoneuroendocrinology* 2000; 25(8): 765–771.
213. Worboys S, Kotsopoulos D, Teede H et al. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. *J Clin Endocrinol Metab* 2001; 86(1): 158–161.
214. Van Anders SM, Hampson E. Waist-to-hip ratio is positively associated with bioavailable testosterone but negatively associated with sexual desire in healthy Premenopausal women. *Psychosom Med* 2005; 67(2): 246–250.
215. Janssen I, Powell LH, Crawford S et al. Development of the metabolic syndrome through menopause: The Study of Women's Health Across the Nation (SWAN). *Circulation* 2007; 115(8).
216. Gordon C, Wallace DJ, Shinada S et al. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. *Rheumatology* (Oxford) 2008; 47(3): 334–338.
217. Ehrenreich H, Halaris A, Ruether E et al. Psychoendocrine sequelae of chronic testosterone deficiency. *J Psychiatr Res* 1999; 33(5): 379–387.
218. Gold EB, Colvin A, Avis N et al. Longitudinal analysis of vasomotor symptoms and race/ethnicity across the menopausal transition: Study of women's health across the nation. *Am J Public Health* 2006; 96(7): 1226–1235.
219. Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine. *Cancer Res* 1975; 35(5): 1341–1353.
220. Lemon HM, Kumar PF, Peterson C et al. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. *Cancer* 1989; 63(9): 1685–1692.
221. Head KA. Estriol: Safety and efficacy. *Altern Med Rev* 1998; 3(2):101–113.
222. Itoi H, Minakami H, Iwasaki R et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. *Maturitas* 2000; 36(3): 217–222.
223. Koloszar S, Kovacs L. [Treatment of climacteric urogenital disorders with an estriol-containing ointment]. *Orv Hetil* 1995; 136(7): 343–345.
224. Sonni R, Bondi G, Travaglini S. [Presenile and senile vulvovaginitis. Topical hormonal treatment with estriol]. *Minerva Ginecol* 1991; 43(4): 177–179.
225. Yang TS, Tsan SH, Chang SP et al. Efficacy and safety of estriol replacement therapy for climacteric women. *Zhonghua Yi Xue Za Zhi* (Taipei) 1995; 55(5): 386–391.
226. Morrison JH, Brinton RD, Schmidt PJ et al. Estrogen, menopause, and the aging brain: How basic neuroscience can inform hormone therapy in women. *J Neurosci* 2006; 26(41): 10332–10348.
227. Hargrove JT, Maxson WS, Wentz AC et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. *Obstet Gynecol* 1989; 73(4): 606–612.
228. Giuliani A, Concin H, Wieser F et al. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal

- symptoms and lipid metabolism]. *Wien Klin Wochenschr* 2000; 112(14): 629–633.
229. Seely EW, Walsh BW, Gerhard MD et al. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. *Hypertension* 1999; 33(5): 1190–1194.
 230. Polanczyk MJ, Carson BD, Subramanian S et al. Cutting edge: Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. *J Immunol* 2004; 173(4): 2227–2230.
 231. Yue T, Wang X, Loudon CS et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. *Mol Pharmacol* 1997; 51(6): 951–962.
 232. Weiland N. Estradiol selectively regulates agonist binding sites on the N-Methyl-D-Aspartate receptor complex in the CA1 region of the hippocampus. *Endocrinology* 1992; 131(2): 662–668.
 233. van den Heuvel MW, van Bragt AJ, Alnabawy AK et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch, and an oral contraceptive. *Contraception* 2005; 72(3): 168–174.
 234. Richman S, Edusa V, Fadiel A et al. Low-dose estrogen therapy for prevention of osteoporosis: Working our way back to monotherapy. *Menopause* 2006; 13(1): 148–155.
 235. Cohen LS, Soares CN, Poitras JR et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: A preliminary report. *Am J Psychiatry* 2003; 160(8): 1519–1522.
 236. Yue T, Wang X, Loudon CS et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. *Mol Pharmacol* 1997; 51(6): 951–962.
 237. Fotsis T, Zhang Y, Pepper MS et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. *Nature* 1994; 368(6468): 237–239.
 238. Totta P, Acconcia F, Leone S et al. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: Involvement of estrogen receptor alpha and beta signaling. *IUBMB Life* 2004; 56(8): 491–499.
 239. Hwang J, Mack WJ, Xiang M et al. Long-term effect of estrogen replacement on plasma nitric oxide levels: Results from the estrogen in the prevention of atherosclerosis trial (EPAT). *Atherosclerosis* 2005; 181(2): 375–380.
 240. Joffe H, Hall JE, Gruber S et al. Estrogen therapy selectively enhances prefrontal cognitive processes: A randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. *Menopause* 2006; 13(3): 411–422.
 241. Greene JG. A factor analytic study of climacteric symptoms. *J Psychosom Res* 1976; 20(5): 425–430.
 242. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23: 56–62.
 243. Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol* 1959; 32(1): 50–55.
 244. Maier W, Buller R, Philipp M et al. The Hamilton Anxiety Scale: Reliability, validity and sensitivity to change in anxiety and depressive disorders. *J Affect Disord* 1988; 14(1): 61–68.
 245. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. *J Psychosom Res* 1967; 11(2): 213–218.
 246. Siegler IC. The UNC Alumni Heart Study (UNCAHS) Strain Scale. Durham, Duke University Behavioral Medicine Research Center; 1989.